All articles by Sophie Cairns

Sophie Cairns

Pricing and Market Access

China’s latest NRDL update continues to exclude foreign PD-1 inhibitors, favours rare disease drugs

Pricing and Market Access

Delytact: The world’s first oncolytic virotherapy for brain cancer

Pricing and Market Access

Japan’s new CEA-based price adjustments set to maintain pricing pressure on innovative drugs

Pricing and Market Access

China’s young biosimilars sector

Pricing and Market Access

South Korean pharma dreams struggle

Pricing and Market Access

Inconsistent application of pricing policies in China contributes to pockets of high prices

Pricing and Market Access

HTA adoption in Asian emerging pharma markets

Pricing and Market Access

Regulatory convergence or divergence for Asian pharma

Pricing and Market Access

Culture shift at Takeda a sign of things to come

Pricing and Market Access

US tariffs likely to mostly affect US generics makers